Sign in
Taking people in United StatesNo phase

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Key facts

Who runs it
Children's Hospital Medical Center, Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Status
Recruiting
People taking part
115 people, planned
Started
17 Jan 2017
Expected to end
30 Jan 2030
Type of study
Observational
Record updated
19 August 2026

Who can take part

Age
6 years to 23 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Age 6-23 years old
  • Established or suspected clinical diagnosis of AIH or PSC

Who cannot take part

  • Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia)
  • History of liver transplantation
  • Chronic Hepatitis B or untreated hepatitis C virus infection
  • Diagnosis of cardiac hepatopathy
  • Diagnosis of Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease
  • Skin conditions which could be aggravated by MREL (i.e. Epidermolysis bullosa)
  • Pregnancy
  • Diagnosis of cystic fibrosis or biliary atresia

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Autoimmune liver disease or primary sclerosing cholangitis or autoimmune hepatitis

This trial is currently available in United States.

  • Cincinnati Childrens Hospital Medical CenterCincinnati, United StatesContact: Alexander Miethke, MDTaking people

About the trial

What the trial wants to find out

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.

The group in the trial

  • Patients with autoimmune liver disease

    Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level \>1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled. Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT\>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease
Criteria questions
Built from NCT03175471, who can take part
Publications
Record updated
19 August 2026